HALOZYME THERAPEUTICS INC (HALO)
US40637H1095 - Common Stock
HALOZYME THERAPEUTICS INC
NASDAQ:HALO (12/24/2024, 8:18:31 PM)
After market: 47.54 0 (0%)47.54
+0.38 (+0.81%)
Company Profile
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 373 full-time employees. The company went IPO on 2003-01-30. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. The company also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. The company markets and sells Hylenex recombinant, which is a formulation of rHuPH20. The company markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
Company Info
HALOZYME THERAPEUTICS INC
12390 El Camino Real
San Diego CALIFORNIA 92121-1345
P: 18587948889
CEO: Helen I. Torley
Employees: 373
Website: https://www.halozyme.com/
HALO News
2 days ago - Market News VideoInteresting HALO Put And Call Options For February 2025
8 days ago - ChartmillIs NASDAQ:HALO on the Verge of a Major Breakout as a Strong Growth Stock?Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation.
10 days ago - ChartmillLooking for growth without the hefty price tag? Consider NASDAQ:HALO.NASDAQ:HALO, a growth stock which is not overvalued.
13 days ago - ChartmillIn a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.For those who appreciate value investing, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a compelling option with its solid fundamentals.
a month ago - Halozyme Therapeutics, Inc.Halozyme to Present at Upcoming Investor Conferences/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the executive leadership team are scheduled to present...
a month ago - Halozyme Therapeutics, Inc.Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire...
HALO Twits
Here you can normally see the latest stock twits on HALO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
